Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Davidson ZhaoEntsar EladlMojgan ZarifJosé-Mario Capo-ChichiAndre SchuhAtenafu G EshetuMark MindenHong ChangPublished in: Cancer medicine (2022)
AML-MRC defines a very-high-risk subentity of AML in which novel therapies should be explored.